Future of convection-enhanced delivery in the treatment of brain tumors.

Gliomas are one of the most lethal forms of cancer. The poor prognosis associated with these malignant primary brain tumors treated with surgery, radiotherapy and chemotherapy has led researchers to develop new strategies for cure. Interstitial drug delivery has been the most appealing method for the treatment of primary brain tumors because it provides the most direct method of overcoming the barriers to tumor drug delivery. By administering therapeutic agents directly to the brain interstitium and, more specifically, to tumor-infiltrated parenchyma, one can overcome the elevated interstitial pressure produced by brain tumors. Convection-enhanced delivery (CED) has emerged as a leading investigational delivery technique for the treatment of brain tumors. Clinical trials utilizing these methods have been completed, with mixed results, and several more are being initiated. However, the potential efficacy of these drugs may be limited by ineffective tissue distribution. The development of computer models/algorithms to predict drug distribution, new catheter designs, and utilization of tracer models and nanocarriers have all laid the groundwork for the advancement of CED. In this review, we summarize the recent past of the clinical trials utilizing CED and discuss emerging technologies that will shape future CED trials.

[1]  E. Winer,et al.  Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Vortmeyer,et al.  Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. , 2005, Journal of neurosurgery.

[3]  Peter Dickinson,et al.  Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. , 2008, Journal of neurosurgery.

[4]  I. Pastan,et al.  A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin Is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4 (*) , 1995, The Journal of Biological Chemistry.

[5]  Raj K Puri,et al.  CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS , 2007, Neurosurgery.

[6]  Volker Sturm,et al.  Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma , 2003, Annals of neurology.

[7]  Raghu Raghavan,et al.  Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. , 2007, Neuro-oncology.

[8]  E. Oldfield,et al.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.

[9]  Seunguk Oh,et al.  Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. , 2007, Journal of neurosurgery.

[10]  Raghu Raghavan,et al.  Convection-enhanced delivery of therapeutics for brain disease, and its optimization. , 2006, Neurosurgical focus.

[11]  S E Maier,et al.  Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. , 2001, Cancer research.

[12]  K. Schlingensiepen,et al.  Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[13]  Michael Weaver,et al.  Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[14]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[15]  Daniel L. Silbergeld,et al.  Convection-enhanced delivery of cintredekin besudotox (interleukin-13- PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas , 2007 .

[16]  S. Eastman,et al.  Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience , 2009, Journal of Neuro-Oncology.

[17]  M. Rogawski.  Convection-enhanced delivery in the treatment of epilepsy , 2009, Neurotherapeutics.

[18]  P F Morrison,et al.  Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.

[19]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Pastan,et al.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Ryuta Saito,et al.  Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. , 2005, Brain research. Brain research protocols.

[22]  John W. Park,et al.  Real-time Imaging and Quantification of Brain Delivery of Liposomes , 2006, Pharmaceutical Research.

[23]  Mitchel S Berger,et al.  Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. , 2008, Neuro-oncology.

[24]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Barry W Wessels,et al.  Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients , 2005, Neurosurgery.

[26]  Christoph Pedain,et al.  INTRACEREBRAL INFUSATE DISTRIBUTION BY CONVECTION‐ENHANCED DELIVERY IN HUMANS WITH MALIGNANT GLIOMAS: DESCRIPTIVE EFFECTS OF TARGET ANATOMY AND CATHETER POSITIONING , 2007, Neurosurgery.

[27]  W. Hall,et al.  Convection-enhanced delivery of targeted toxins for malignant glioma , 2006, Expert opinion on drug delivery.

[28]  W. Hall,et al.  Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice , 2006, International journal of cancer.

[29]  R Bucholz,et al.  Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. , 2003, Acta neurochirurgica. Supplement.

[30]  W. Hall,et al.  Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. , 2006, Neurosurgical focus.

[31]  W. Hall,et al.  Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. , 2002, Journal of the National Cancer Institute.

[32]  Ryuta Saito,et al.  Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain , 2005, Experimental Neurology.

[33]  P. Choyke,et al.  A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agents. , 2008, Contrast media & molecular imaging.

[34]  Anthony Asher,et al.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[35]  R. Puri,et al.  Interleukin-4-Pseudomonas Exotoxin Chimeric Fusion Protein for Malignant Glioma Therapy , 2003, Journal of Neuro-Oncology.

[36]  P F Morrison,et al.  Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[37]  Ryuta Saito,et al.  Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. , 2005, Journal of neurosurgery.

[38]  W. Dandy,et al.  REMOVAL OF RIGHT CEREBRAL HEMISPHERE FOR CERTAIN TUMORS WITH HEMIPLEGIA: PRELIMINARY REPORT , 1928 .

[39]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Coleman,et al.  Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. , 2007, AJR. American journal of roentgenology.

[41]  S. Maier,et al.  Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. , 2005, Cancer research.

[42]  S. Maier,et al.  Convection-Enhanced Drug Delivery of Interleukin-4 Pseudomonas Exotoxin (PRX321): Increased Distribution and Magnetic Resonance Monitoring , 2009, Journal of Pharmacology and Experimental Therapeutics.